Coronary Artery AtherosclerosisRAVENTANCT07552948
Radial vs Vena No-Touch Assessment
A study testing radial artery graft and no-touch vein graft in people with Coronary Artery Atherosclerosis, run by Tomsk Cardiology Research Institute at 1 site in Russia.
Trial summary
This study examines the outcomes of coronary artery bypass grafting (CABG) in women at 1 year after surgery. A randomized controlled trial is planned, including a comparative analysis of two observed groups depending on the chosen conduit for revascularization of the circumflex artery. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Coronary Artery Atherosclerosis
- What is being tested?
- radial artery graft and no-touch vein graft
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 110 participants
- Where
- 1 siteRussia
- Study dates
- 6 Apr 2026to Apr 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Three-vessel disease involving the target circumflex artery with stenosis ≥70% and a diameter ≥1.5 mm
- Females aged 18 years and older
- Signed informed consent
- Clinical indications for coronary revascularization (refractory angina/transient myocardial ischemia according to noninvasive tests)
Who cannot join
- Previous cardiac surgery of any type, including CABG
- Combined procedures
- Ineligibility for venous or radial artery harvesting as determined by preoperative Doppler flowmetry or clinical examination that would compromise graft patency.
- Acute myocardial ischemia
- EF less than 35%
- CKD 4.5
- Inability to understand the nature, scope, and consequences of the clinical trial, or to provide written informed consent due to cognitive impairment or mental illness.
- Life expectancy less than 1 year due to non-cardiac diseases.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Russia1 site, 1 recruiting
- Recruiting
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
Tomsk, 634012
Yuri Y. Vesherskiy, MD, PhD, +79039512225, vjj@cardio-tomsk.ru
About this study
Official title: A Comparative Study of the Effectiveness of Radial Artery and No-touch Vein in Coronary Artery Bypass Grafting in Women
This study examines the outcomes of coronary artery bypass grafting (CABG) in women at 1 year after surgery. A randomized controlled trial is planned, including a comparative analysis of two observed groups depending on the chosen conduit for revascularization of the circumflex artery. The main group is supposed to include 55 patients undergoing CABG with the use of the radial artery, while the control group will include 55 patients undergoing CABG with the use of the great saphenous vein prepared using the no-touch technique.
Read the detailed description
The Raventa trial is a prospective, unblinded, randomized single centre trial comprising 110 subjects. Women with left main and/or multivessel disease will be randomized to radial artery (RA) or no-touch vein (NV) grafts to the left coronary system in a 1:1 fashion. The primary outcome will be the ratio of functioning and closed radial artery and no-touch vein bypass grafts in the groups one year after surgery. The secondary outcomes will be:
- Difference in the composite rate of major adverse cardiac and cerebrovascular events (MACCE) between the groups at 30 days and 12 months after the procedure. For the purposes of this study, MACCE components include all-cause mortality, stroke, myocardial infarction and/or repeat revascularization.
- Difference in the incidence of complications (hemorrhagic, neurological, infectious, arrhythmological) between the groups.
- Difference in angina class between the groups at one year after the procedure.
In all patients, 1 internal thoracic artery will be anastomosed to the left anterior descending coronary artery. For patients randomized to the NV group, saphenous no-touch vein grafts will be used for all non-left anterior descending target vessels. For patients randomized to the RA group, the main target vessel of the lateral wall will be grafted with radial artery. Additional grafts can be saphenous veins or supplemental arterial conduits at the surgeon's discretion.
Screening. The screening period will last from the patient's admission to the hospital until the day before surgery. Eligibility for this study will be determined based on the results of routine clinical and instrumental examinations, conducted in accordance with existing clinical practice standards and the Cardiology Research Institute's protocols for this patient category, including coronary angiography, ultrasound, and general clinical tests.
Follow-up period: 12 months after surgery. During this period, information on the disease course and intervention outcomes will be collected. Data on secondary endpoints 1 and 2 will be collected within 30 days postoperatively. A follow-up assessment of the study participants' vital status will be performed in 12 months after surgery, identifying MACCE (all-cause mortality, repeat revascularization, stroke, and myocardial infarction) as well as examining coronary bypasses to assess the primary endpoint and secondary endpoints 1 and 3.
- Conditions
- Coronary Artery Atherosclerosis
- Being tested
- radial artery graft, no-touch vein graft
- Keywords
- Coronary artery atherosclerosis, no-touch vein, radial artery
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
radial artery graftProcedure or surgery
Circumflex artery territory revascularization using the radial artery graft
no-touch vein graftProcedure or surgery
Circumflex artery territory revascularization using a no-touch vein graft
| Study group | Role | What they receive |
|---|---|---|
| Radial artery | Active comparator | Radial artery as a conduit for the circumflex artery territory in 55 patients undergoing coronary artery bypass grafting Receives: Procedure: radial artery graft |
| No-touch great saphenous vein | Active comparator | No-touch great saphenous vein graft for revascularization of the circumflex artery territory in 55 patients during coronary artery bypass grafting Receives: Procedure: no-touch vein graft |
What is being measured
The primary outcome is the main question the study is designed to answer.
The ratio of functioning and closed shunts in both groups
Measured: during follow-up time - 12 months
Secondary outcomes (3)
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) (number of cases)
Between groups at 30 days and 12 months after surgery.
Measured: Early postoperative (up to 2 weeks)/ Remote postoperative (up to 2 months)
Complications (percent)
Complication rates between groups
Measured: Early postoperative (up to 2 weeks)
Change in angina class (percent)
one year after surgical revascularization in the compared groups
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Apr 2026
- Study start6 Apr 2026
- Primary completionApr 2027 (estimated)
- Study completionApr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery AtherosclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 110 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tomsk Cardiology Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Yuri Y. Veshersky, MD, PhD, Principal investigator, Cardiology Research Institute, Tomsk National Research Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07552948
- Sponsor's protocol ID
- 294
- Acronym
- RAVENTA
- Status last verified
- Apr 2026
- First submitted
- 13 Apr 2026
- Last updated
- 27 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Comparative Study of the Effectiveness of Radial Artery and No-touch Vein in Coronary Artery Bypass Grafting in Women
- ClinicalTrials.gov ID
- NCT07552948
- Acronym / sponsor ID
- RAVENTA / 294
- Conditions
- Coronary Artery Atherosclerosis
- Keywords
- Coronary artery atherosclerosis, no-touch vein, radial artery
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 110 participants (estimated)
- Lead sponsor
- Tomsk Cardiology Research InstituteUniversity, hospital or other
- Study start
- 6 Apr 2026 (actual)
- Primary completion
- Apr 2027 (estimated)
- Study completion
- Apr 2029 (estimated)
- First posted
- 27 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study examines the outcomes of coronary artery bypass grafting (CABG) in women at 1 year after surgery. A randomized controlled trial is planned, including a comparative analysis of two observed groups depending on the chosen conduit for revascularization of the circumflex artery. The main group is supposed to include 55 patients undergoing CABG with the use of the radial artery, while the control group will include 55 patients undergoing CABG with the use of the great saphenous vein prepared using the no-touch technique.
Detailed description
The Raventa trial is a prospective, unblinded, randomized single centre trial comprising 110 subjects. Women with left main and/or multivessel disease will be randomized to radial artery (RA) or no-touch vein (NV) grafts to the left coronary system in a 1:1 fashion. The primary outcome will be the ratio of functioning and closed radial artery and no-touch vein bypass grafts in the groups one year after surgery. The secondary outcomes will be:
- Difference in the composite rate of major adverse cardiac and cerebrovascular events (MACCE) between the groups at 30 days and 12 months after the procedure. For the purposes of this study, MACCE components include all-cause mortality, stroke, myocardial infarction and/or repeat revascularization.
- Difference in the incidence of complications (hemorrhagic, neurological, infectious, arrhythmological) between the groups.
- Difference in angina class between the groups at one year after the procedure.
In all patients, 1 internal thoracic artery will be anastomosed to the left anterior descending coronary artery. For patients randomized to the NV group, saphenous no-touch vein grafts will be used for all non-left anterior descending target vessels. For patients randomized to the RA group, the main target vessel of the lateral wall will be grafted with radial artery. Additional grafts can be saphenous veins or supplemental arterial conduits at the surgeon's discretion.
Screening. The screening period will last from the patient's admission to the hospital until the day before surgery. Eligibility for this study will be determined based on the results of routine clinical and instrumental examinations, conducted in accordance with existing clinical practice standards and the Cardiology Research Institute's protocols for this patient category, including coronary angiography, ultrasound, and general clinical tests.
Follow-up period: 12 months after surgery. During this period, information on the disease course and intervention outcomes will be collected. Data on secondary endpoints 1 and 2 will be collected within 30 days postoperatively. A follow-up assessment of the study participants' vital status will be performed in 12 months after surgery, identifying MACCE (all-cause mortality, repeat revascularization, stroke, and myocardial infarction) as well as examining coronary bypasses to assess the primary endpoint and secondary endpoints 1 and 3.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Radial artery | Active comparator | Procedure: radial artery graftRadial artery as a conduit for the circumflex artery territory in 55 patients undergoing coronary artery bypass grafting |
| No-touch great saphenous vein | Active comparator | Procedure: no-touch vein graftNo-touch great saphenous vein graft for revascularization of the circumflex artery territory in 55 patients during coronary artery bypass grafting |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Three-vessel disease involving the target circumflex artery with stenosis ≥70% and a diameter ≥1.5 mm
- Females aged 18 years and older
- Signed informed consent
- Clinical indications for coronary revascularization (refractory angina/transient myocardial ischemia according to noninvasive tests)
Key exclusion criteria (8 listed)
- Previous cardiac surgery of any type, including CABG
- Combined procedures
- Ineligibility for venous or radial artery harvesting as determined by preoperative Doppler flowmetry or clinical examination that would compromise graft patency.
- Acute myocardial ischemia
- EF less than 35%
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| radial artery graftCircumflex artery territory revascularization using the radial artery graft | Procedure or surgery | Radial artery |
| no-touch vein graftCircumflex artery territory revascularization using a no-touch vein graft | Procedure or surgery | No-touch great saphenous vein |
Primary outcome
The ratio of functioning and closed shunts in both groups
Time frame: during follow-up time - 12 months
3 secondary outcomes
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) (number of cases)
Time frame: Early postoperative (up to 2 weeks)/ Remote postoperative (up to 2 months)
Complications (percent)
Time frame: Early postoperative (up to 2 weeks)
Change in angina class (percent)
Time frame: Through study completion, an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Coronary Artery Atherosclerosis
Not yet recruiting
GOT VOICE Feasibility With In-Person Group Singing
Elderly, Coronary Arterial Disease (CAD)
RecruitingObservational study
Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry
Cardiovascular Diseases
Recruiting
Lifewise Preventive Video Education in Primary Care
Prevention Harmful Effects, Health Maintenance
RecruitingPhase 4
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Active, not recruiting
Comparison of Vessel-FFR Versus FFR in Intermediate Coronary Stenoses
Coronary Artery Disease, Coronary Artery Stenoses
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yuri Y. Veshersky, MD, PhD principal investigator
Cardiology Research Institute, Tomsk National Research Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing radial artery graft and no-touch vein graft in people with Coronary Artery Atherosclerosis, run by Tomsk Cardiology Research Institute at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Vasily V. Zatolokin, PhD (+79138490545, zatolokin@cardio-tomsk.ru), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The ratio of functioning and closed shunts in both groups (time frame: during follow-up time - 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2026.